As reported in Korea Biomedical Review by Lee Han-Soo, Kainos Medicine plans on launching clinical trials testing its KM-819 on multiple system atrophy (MSA) patients. Also known as Shy-Drager syndrome, it is a rare degenerative brain disease characterized by symptoms of Parkinson’s disease, which includes slowness of body movement, stiffness, as well as autonomic nervous disorders such as dysuria and orthostatic hypertension. Approximately 300,000 MSA patients exist worldwide including 2,000 in Korea. MSA results from accumulation and aggregation of alpha-synuclein, a protein that helps neurotransmission, in the midbrain and basal ganglia of the brain as well as parietal and cerebellar nervous system and glial cells.
Kainos Medicine will expand its indications for KM-819, which completed phase 1 clinical trials with Parkinson’s disease and enter phase 2 clinical trials early. KM-819 is a new drug candidate targeting FAS-associated factor 1, which inhibits the death of dopamine-secreting cells, thereby stopping the progression or slowing the progress of the disease.Source: Korea Biomedical Review